Background We assessed differences in predicted breast cancer (BC) mortality rates, across Europe, by 2020, taking into account changes in the time trends of BC mortality rates during the period 2000-2010. Methods BC mortality data, for 27 European Union (EU) countries, were extracted from the World Health Organization mortality database. First, we compared BC mortality data between time periods 2000-2004 and 2006-2010 through standardized mortality ratios (SMRs) and carrying out a graphical assessment of the age-specific rates. Second, making use of the base period 2006-2012, we predicted BC mortality rates by 2020. Finally, making use of the SMRs and the predicted data, we identified a clustering of countries, assessing differences in the time trends between the areas defined in this clustering.
Introduction
Recent estimates have shown that breast cancer (BC) is still the most frequently reported cancer among European women [1] . However, changes in the burden of cancer mortality are expected to be observed across Europe in the short term, with BC mortality rates surpassed by those of lung cancer among young age groups [2] . These changes are related to improvements in survival due to the efficacy of treatments in parallel with earlier detection of cancer with screening [3] . Previous studies in Europe have not assessed, with precision, what amount of variability in mortality is due to screening and/or treatment [4] . It is likely that the variation observed in the BC burden across Europe is attributable to various screening activities in operation, differences in diagnosis and treatment, and in the distribution of known risk factors for BC [4] .
In 2003, the European Parliament (EP) adopted a Resolution (A5-0159/2003) which aims to diminish disparities in access to BC screening and treatment [5] . Since then, improvements have been observed in BC survival in some countries, notably in western and northern countries, and this has acted as an incentive for new members of the EU, and other Eastern European countries, to reduce health inequalities in access to screening and treatment, and thus reduce the gaps in BC mortality trends [3, 6] .
In this study, we examined changes in the variability of BC mortality patterns in EU-27 countries, during the period 2000-2010, comparing two 5-year periods: 2000-2004 and 2006-2010 . Finally, making use of the most recent trends in BC mortality rates, we compared the observed BC mortality rates, in 2010, with rates predicted for 2020 and identified two clusters of countries associated with these patterns of BC mortality.
Methods

Data
Data on BC mortality were extracted from the World Health Organization mortality database for 27 countries in Europe during the period 1990-2012 [7] .
Age-specific BC mortality rates and age-standardised mortality rates (ASMRs) to the World Standard Population were calculated for all countries. In cases where agespecific data were missing, rates were estimated through linear interpolation. The latter was performed for Belgium (2000) (2001) (2002) , Italy (2004 Italy ( -2005 , Portugal (2004 Portugal ( -2006 , and Poland (1997) (1998) . Data for Slovenia were available for 2010 and BC mortality data in 2011-2012 were estimated by applying the BC age-specific rates in 2010 to the population distribution in 2011-2012. Finally, BC mortality data for Slovakia in 1990 were computed as the mean of the age-specific rates between 1992 and 1993. Based on these data, we carried out four statistical models, within the Bayesian framework, assuming that the number of deaths follows a Poisson distribution. Breast cancer mortality data were arranged in eighteen 5-year age groups (from 0-4 to 85-90 years) throughout the analysis.
Data on national populations were extracted from the Eurostat Database, maintained by the European Commission [8] . The latter takes into account age-specific mortality rates and international net migration.
Analytical approach
Changes in the BC mortality rates comparing the periods 2000-2004 and 2006-2010 All the calculations assumed a Poisson distribution for the number of deaths under a Bayesian approach [9] , as an extension of the classic predictive method.
Standardized mortality ratios (SMRs) were calculated to compare the risk of dying from BC in different periods. The ratios were computed as the number of observed BC deaths, in a given period, with the number of expected BC deaths if the age-specific death rates were the same as in another (reference) period Graphical assessment of the changes in the age-specific BC mortality rates comparing the periods 2000-2004 and 2006-2010 Age-specific mortality rates were smoothed through an autoregressive Bayesian model imposing a temporal structure on model parameters [10] . We assumed that the number of deaths from BC, i.e. D, followed a Poisson distribution, D ip $ Poisson ðl ip Þ, where i refers to the ith age group, i ¼ f1; 2; . . .; 17; 18g j f0 À 4; 5 À 9; . . .; 80 À 84; 85 À 89g and p is the period, p = {1, 2} | {2000-2004, 2006-2010}. Assuming that the expected age-specific BC mortality rate is
, where Y pt are the person-years at risk, we smoothed these rates through the model logðk ip Þ ¼ c þ a ip where a ip are the age-specific effects and c an intercept which guarantees P i a ip ¼ 0. To smooth rates, we imposed a temporal autoregressive structure of order 2 for the age effects [10] a ip $ Nða iÀ1p ; s p Þ where s p is the prior precision for which we assumed s p $ Gammað0:001; 0:001Þ. Once the model was fitted, we simulated the posterior distribution of k i;2006À2010 and k i;2000À2004 and then we obtained a posterior
, which is the ratio of agespecific BC mortality rates between periods.
Projections of breast cancer mortality in 2020 and cluster analysis Making use of the eighteen 5-year age groups (from 0-4 to 85-90 years), for the prediction base of 2006-2012, rates were projected to 2020 using a Bayesian log-linear age-specific model for each country [9] . Based on previous experience, the choice of a minimum prediction base length of 5 years can be considered adequate for projections [9] . Projections were made by extrapolating the rates of the model fitted to 2006-2012 to the unobserved years 2013-2020 and plugging in the age-specific population counts for those years to obtain the predicted number of deaths [9] . The use of these population counts is needed since these include the changes in age distribution which may affect future predictions [9, 10] . Therefore, the model took into account changes in age distribution for the period 2013-2020. These population counts were obtained from the United Nations World Population Prospects for the years 2013-2020 [11] .
Finally, we assessed changes in the risk of death from BC comparing the years 2010 and 2020 by groups of countries through a weighted clustering analysis. Making use of the predicted number of BC deaths during 2020, for each country, we estimated the ASMRs during 2020 and the SMR in 2020 using as reference population that of 2010. Aggregating the ASMRs and SMRs, in a data set, during the whole study period, a hierarchical weighted clustering analysis (making use of the Ward aggregating method) was used to identify clusters of countries [12] .
Reporting and interpretation of results
Based on the posterior distribution of the estimates, we calculated the 95% credible intervals (95% CI) for SMRs and age-specific ratios. For a 95% CI, the value of interest SMR or age-specific ratio lies with a 95% probability in the interval. On the other hand, the 95% prediction interval of the age-specific deaths for 2020 was used for prediction purposes. All the analyses were carried out through R using the library INLA [13] (See supplementary material for additional Figures and R code).
Results are presented by grouping countries by European regions. Population screening programmes as a reference for the interpretation of the data are summarized in the Supplementary Material (see section: ''The situation of BC screening programmes in the European countries considered in this study'' and Table S2 ). The division in European regions was North, Western, Southern and Eastern European countries according to the United Nations geo scheme for Europe created by the United Nations Statistics division (https://unstats. un.org/unsd/methodology/m49/).
In the presentation of results, we marked those countries where screening activities were introduced after 2005 [5] . For those countries with screening activities, Figs. 1, 2, 3 and 4 include vertical lines corresponding to age groups included in the screening programmes. To help with the interpretation of the results presented in these figures, the start of screening activities in each country and the target age groups must be taken into account. For this purpose, see Table S1 of the Supplementary material. (Fig. 2) . Figures 3 and 4 compare the BC mortality rates for 2010 and the 95% prediction interval for the age-specific BC mortality rates for 2020. The decreasing trend of BC mortality detected during 2000-2010 could level off by 2020 in these countries where the 95% prediction intervals for BC mortality rates in 2020 include the observed BC mortality rates in 2010. In those age groups where the 95% prediction interval lies below the observed rates in 2010, a decrease in BC mortality rates is expected by 2020. Given this observation, for some of the northwestern countries (Fig. 3) , the predicted BC mortality rates might decrease compared with 2010. This is the case for Denmark (50-59 years), Ireland (60-69 years), the Netherlands (45-64 years), Sweden (40-64 years) and UK (50-69 years). In Eastern European countries (Fig. 4) , a similar trend might occur in the Czech Republic ([45 years) and Hungary (45-64 years). BC mortality rates might increase in advanced age groups (beyond 69 years of age) in Estonia, Latvia and Lithuania (see 
Cluster analysis
Making use of the predicted number of BC deaths during 2013-2020 we estimated the ASMRs for this time period. In addition, we evaluated the changes in the risk of death from BC between 2010 and 2020 calculating the SMR in 2020 with respect to 2010 (see Supplementary Table S1 ). We used ASMRs and SMR data in a weighted clustering analysis where our dataset included six columns: Fig. 5a , where one of the clusters included Estonia, Latvia and Lithuania, Greece, Croatia, Bulgaria, Poland, Romania and Slovakia. Figure 5b , c shows that the differences in the time trend of BC mortality rates between these two groups of countries might disappear by 2020 since ASMRs might converge towards similar values.
Discussion
This study has shown that predicted BC mortality rates may have different trends depending on the country and European Region. Our predictions by 2020 show two patterns of BC mortality trends: (1) a non-decreasing trend mainly due to the increase in BC mortality rates from 2010 among women [69 years, detected in nine countries, eight out of these from Eastern Europe, and (2) a decrease towards a plateau of these rates in the remaining countries. This divergence could mean that BC mortality rates between European regions might diminish and converge towards similar values by 2020. However, one must take into account that differences between countries still remain.
Several limitations should be noted. First, BC mortality trends depend on previous trends in both incidence and survival [14] ; therefore, using information on the time trends of these factors could lead to better interpretation of BC mortality predictions. We interpret our results taking into account this limitation. Second, a major limitation of the model is that it assumes a stability of a large amount of variables such as the economic situation and, related to this, universal access to the healthcare system. Taking this limitation into account differences in the targeted population that is screened could explain the differences between countries and also the impact on the BC mortality predictions. Changes of these variables may affect the predictions presented here.
The most recent estimates of cancer incidence and survival in Europe have shown that some Eastern European countries have the lowest BC incidence rates [4] and the lowest 5-year relative survival of BC among European countries [15] . In Bulgaria, Czech Republic, Poland, Slovakia, Estonia, Latvia and Lithuania, BC incidence rates rose during 1998-2007 among women aged 50-74 [4] whereas 5-year relative survival remained below the European average during a similar time period [15] . The Czech Republic shows the highest BC incidence and survival rates among these countries [15] . Therefore, our results suggest that the combined effect of BC diagnosis, treatment, management and organization of BC care, and differences in BC incidence between countries, may influence the variability observed in BC mortality rates [1, 16, 17] .
We found that, in most European countries, rate ratios were clearly below 1 when comparing BC mortality rates in 2006-2010 with those during 2000-2004 (reference period). In addition, advancements in breast cancer treatment, such as oestrogen therapy and adjuvant chemotherapy, and advancements in radiotherapy and surgery [1] , have contributed to a decreasing trend in BC mortality rates. Selective oestrogen receptor modulators (such as tamoxifen and raloxifene) have also been assessed for primary prevention of breast cancer although their impact on mortality is likely to be limited since the chemopreventive use of these drugs has been uncommon [16] . As stated above, the implementation of organized or opportunistic breast cancer screening in many European countries is a key factor in explaining BC trends [4] . Organized mammographic screening aims to detect cancer at an earlier stage and thus reduce the incidence of advanced cancer [18] and could improve participation and equity of access [19] [20] [21] [22] [23] [24] [25] . Some other studies, however, have suggested that [26, 27] . Uncertainty about the magnitude of the effect of screening on BC mortality reduction has been discussed elsewhere [27] [28] [29] [30] .
It is important to point out that the most recent cancer mortality trends and predictions in Europe have shown, in general, that BC deaths are declining towards a plateau in the EU [2] . In the short term, other cancer sites, such as lung cancer [1, 2] , may surpass the breast, as the leading cancer mortality site in middle-aged women. Our predictions have shown that in Estonia, Latvia and Lithuania, Greece, Croatia, Bulgaria, Poland, Romania and Slovakia, BC mortality rates in 2020 might be higher than those rates in 2010. An explanation could be a rise of BC incidence combined with stabilization of BC survival [4, 15] in these countries. As a result, the predicted slight increase of BC mortality in these countries may lead to converging BC mortality rates among European countries, as our clustering analysis has shown.
A limitation of our study is that predictions were made using the last year with available data for all countries considered, i.e. 2012. The availability of the most recent estimates of future population distributions could show a slightly different scenario since major differences were found in women at advanced age. Large changes in population distributions, and their effect on cancer mortality, are expected to be observed when populations' prediction surpasses 10 years [9] . Diminishing disparities in access to BC screening and treatment is also the goal of the European Parliament Resolution (A5-0159/2003), mentioned in the introduction. Further development of these policies must be supported, as evidence clearly shows that such policies have a positive impact on population health. 
